About 4TEEN4 Pharmaceuticals
Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Undisclosed
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
4teen4.de
Domain Registered Date
Aug 22, 2019
Social & Network Presence
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Series-B+ announced
fundraisingfox.com
- Milestone
X account created (@4teen4G)
29 followers
- Milestone
Website domain registered
4teen4.de
- Capital Raise
Raised $7,280,000 · Series-A
startupintros.com
Investors & Backers
Investor firms and individual backers were not publicly disclosed in available round filings for 4TEEN4 Pharmaceuticals.
Funding History
Series-B+
· Nov 13, 2025
Undisclosed fundraisingfox.com
Series-A
· Jan 1, 2017
$7,280,000 startupintros.com
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026